Safety and Tolerability Clinical Trial
Official title:
Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of AK1967 (Procizumab) in Healthy Male Volunteers
Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of several cardiovascular mediators. During cardiogenic shock, upregulation of the vasoconstrictive molecule angiotensin II is a physiologic and potentially life-saving response aimed at maintaining adequate tissue perfusion. As circulating (c)DPP3 is able to effectively cleave angiotensin II, it may represent a novel factor contributing to hemodynamic instability during cardiogenic shock. Recently, a cDPP3-antagonizing antibody called AK1967 (commonly referred to as Procizumab) has been developed. In animal models of cardiogenic- and septic shock, inhibition of cDPP3 by AK1967 resulted in improved cardiac function and survival. Furthermore, AK1967 has shown an excellent safety record in different preclinical studies. In the current study the safety, tolerability and pharmacokinetics/-dynamics of AK1967 will be investigated in healthy male subjects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06000891 -
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
|
Phase 1 | |
| Active, not recruiting |
NCT05997641 -
Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06181760 -
A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05907382 -
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01952548 -
Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers
|
Phase 1 | |
| Recruiting |
NCT06453824 -
SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT05431634 -
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT03046589 -
DP13 SAD & MAD in Healthy Male Subjects
|
Phase 1 | |
| Recruiting |
NCT06079541 -
Phase 1 Clinical Study of JMKX003142 Tablets
|
Phase 1 | |
| Completed |
NCT05223660 -
A Phase I Pharmacokinetics Study for KT07 Capsule
|
Phase 1 | |
| Completed |
NCT01907867 -
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
|
Phase 1 | |
| Completed |
NCT03809052 -
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03853421 -
Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
|
Phase 1 | |
| Terminated |
NCT03307512 -
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
|
Phase 2 | |
| Completed |
NCT03685708 -
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
| Completed |
NCT03702231 -
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
|
Phase 2 | |
| Completed |
NCT03817346 -
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT01226316 -
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
|
Phase 1 | |
| Completed |
NCT05451667 -
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02029482 -
Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects
|
Phase 1 |